Collegium Pharmaceutical (COLL) Cash & Current Investments (2014 - 2026)

Collegium Pharmaceutical's Cash & Current Investments history runs 13 years deep, the most recent figure standing at $288.5 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 45.87% year-over-year to $288.5 million; the TTM figure through Mar 2026 stood at $288.5 million (up 45.87% YoY), while the FY2025 annual figure was $251.1 million, up 162.76% from the prior year.
• Cash & Current Investments was $288.5 million for Q1 2026 at Collegium Pharmaceutical, up from $251.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $325.5 million in Q2 2023 to a low of $95.6 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $223.4 million across 5 years, with a median of $251.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments soared 165.21% in 2023, then tumbled 69.23% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $173.7 million in 2022, then soared by 78.8% to $310.5 million in 2023, then sank by 69.23% to $95.6 million in 2024, then jumped by 162.76% to $251.1 million in 2025, then advanced by 14.89% to $288.5 million in 2026.
• The last three Cash & Current Investments figures came in at $288.5 million (Q1 2026), $251.1 million (Q4 2025), and $285.9 million (Q3 2025), per Business Quant data.